vimarsana.com
Home
Live Updates
AstraZeneca : Update on CRYSTALIZE evidence trials - Form 6-K -December 01, 2023 at 06:29 am EST : comparemela.com
AstraZeneca : Update on CRYSTALIZE evidence trials - Form 6-K -December 01, 2023 at 06:29 am EST
a2725v
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or...
Related Keywords
China ,
Japan ,
Denmark ,
Washington ,
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Danish ,
Sharon Barr ,
Coll Cardiol ,
Adrian Kemp ,
Securities Exchange ,
Nasdaq ,
European Medicines Agency Lokelma ,
Company Secretary ,
Astrazeneca ,
Astrazeneca Pharmaceuticals ,
Investor Relations Team ,
Diabetes Work Group ,
Commission File Number ,
Foreign Issuer ,
Securities Exchange Act ,
File Number ,
Crick Avenue ,
Regulationst Rule ,
Outcomes Phase ,
Executive Vice President ,
Rare Diseases ,
Dialysate Potassium Concentrations ,
Clinj Am Soc ,
Single Number ,
Communication Worldwide More ,
Individuals Have Kidney ,
Nephrol Dial ,
Global Burden ,
Disease Study ,
Heart Failure ,
American College ,
American Heart Association Joint Committee ,
Clinical Practice ,
Improving Global Outcomes ,
Diabetes Work ,
Treatment Gap Between Clinical Guidelines ,
Renin Angiotensin Aldosterone System ,
Trials Gov ,
Sodium Zirconium Cyclosilicate ,
Chronic Kidney Disease ,
Participants With ,
Arrythmia Related Cardiovascular Outcomes ,
Chronic Hemodialysis With Recurrent Hyperkalemia ,
Medicines Agency ,
Product Characteristics ,
Markets ,
comparemela.com © 2020. All Rights Reserved.